Please use this identifier to cite or link to this item:
Title: A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)
Authors: Ngoi, Natalie YL
Heong, Valerie
Ow, Samuel 
Chay, Wen Yee 
Kim, Hee Seung
Choi, Chel Hun
Goss, Geraldine
Goh, Jeffrey C
Tai, Bee Choo 
Lim, Diana G 
Kaliaperumal, Nivashini
Au, Veonice B
Connolly, John E 
Kim, Jae-Weon
Friedlander, Michael
Kim, Kidong
Tan, David SP 
Keywords: Science & Technology
Life Sciences & Biomedicine
Obstetrics & Gynecology
Issue Date: 1-Aug-2020
Citation: Ngoi, Natalie YL, Heong, Valerie, Ow, Samuel, Chay, Wen Yee, Kim, Hee Seung, Choi, Chel Hun, Goss, Geraldine, Goh, Jeffrey C, Tai, Bee Choo, Lim, Diana G, Kaliaperumal, Nivashini, Au, Veonice B, Connolly, John E, Kim, Jae-Weon, Friedlander, Michael, Kim, Kidong, Tan, David SP (2020-08-01). A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 30 (8) : 1239-1242. ScholarBank@NUS Repository.
Abstract: © IGCS and ESGO 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. BACKGROUND: The optimal treatment of recurrent ovarian clear cell carcinoma remains unknown. There is increasing rationale to support the role of immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in ovarian clear cell carcinoma. PRIMARY OBJECTIVE: To evaluate the efficacy of durvalumab (MEDI-4736) compared with standard chemotherapy in patients with recurrent ovarian clear cell carcinoma. STUDY HYPOTHESIS: Patients with recurrent ovarian clear cell carcinoma treated with durvalumab will have improved progression-free survival compared with those treated with chemotherapy of physician's choice. TRIAL DESIGN: The MOCCA study is a multicenter, open-label, randomized phase II trial in patients with recurrent ovarian clear cell carcinoma, which recruited from eight sites across Gynecologic Cancer Group Singapore (GCGS), Korean Gynecologic-Oncology Group (KGOG), and Australia New Zealand Gynecological Oncology Group (ANZGOG). Enrolled patients were randomized in a 2:1 ratio to receive durvalumab or physician's choice of chemotherapy until disease progression, intolerable toxicity, or withdrawal of patient consent. MAJOR INCLUSION/EXCLUSION CRITERIA: Eligible patients required histologically documented diagnosis of recurrent ovarian clear cell carcinoma, as evidenced by WT1 negativity. All patients must have been of Eastern Cooperative Oncology Group (ECOG) performance status 2 or better, and have had previous treatment with, and progressed or recurred after prior platinum-based chemotherapy. No more than four prior lines of treatment were allowed and prior immune checkpoint inhibitor treatment was not permitted. PRIMARY ENDPOINTS: The primary endpoint was the median progression-free survival following treatment with durvalumab, compared with physician's choice of chemotherapy. Progression-free survival was defined as the time from the first day of treatment to the first observation of disease progression, or death due to any cause, or last follow-up. SAMPLE SIZE: The target sample size was 46 patients. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: Accrual has been completed and results are expected to be presented by mid-2021. TRIAL REGISTRATION: NCT03405454.
ISSN: 1048891X
DOI: 10.1136/ijgc-2020-001604
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physicians choice chemotherapy in recurrent ovarian.pdf1.54 MBAdobe PDF



Page view(s)

checked on Mar 5, 2021


checked on Mar 5, 2021

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.